对SARS冠状病毒具有明显的治疗和预防作用，而且没有明显副作用。利用免疫组织切片证明siRNA对SARS病毒复制的抑制作用（图：自然医学）这项研究取得的重要进展，不仅为人类防治SARS的siRNA药物进入人体临床试验阶段打下了坚实基础，也标志着课题组的技术水平在研究开发siRNA药物领域走入了国际领先行列。看来siRNA介导的RNAi技术无论在医用和基因功能研究方面都展现出诱人的前景，而对于RNAi途径本身最近又有许多研究表明它是沉默，同时也是一种基因表达调控的手段。对于这样的技术生物通当然不会放过，在未来的秋季，生物通将推出系列的RNAi技术文章，看看我们都可以通过什么方式对基因进行干扰。 原文出处：Published online: 21 August 2005; | doi:10.1038/nm1280 Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaqueBao-jian Li1, 2, 7, Qingquan Tang3, 7, Du Cheng2, 7, Chuan Qin4, 7, Frank Y Xie2, 3, Qiang Wei4, Jun Xu3, Yijia Liu3, Bo-jian Zheng5, Martin C Woodle3, Nanshan Zhong6 & Patrick Y Lu3 1 Biotechnology Research Center of Sun Yatsen University, and Key Laboratory of Gene Engineering of Ministry of Education of the State, Guangzhou, China.2 Guangzhou Top Genomics, Ltd., Guangzhou, China.3 Intradigm Corporation, 12115 K Parklawn Drive, Rockville, Maryland 20852, USA.4 Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.5 Department of Pathology, University of Hong Kong, Hong Kong, China.6 Guangzhou Institute of Respiratory Diseases, Guangzhou, China.7 These authors contributed equally to this work.Correspondence should be addressed to Patrick Y Lu [email protected] or Nanshan Zhong [email protected]生物通记者 朱方雨
< 1 > < 2 >
|
